Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program
Nerivio is the First Migraine Treatment Device Offered to Costco Prescription Program Members
NETANYA, Israel and MONTCLAIR, N.J., June 1, 2022 /PRNewswire/ — Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Costco Members Prescription Program (CMPP) is now offering Theranica’s FDA-cleared flagship product Nerivio® at an exclusive rate to Costco Members, marking the first time a migraine treatment device is offered to CMPP members.
Nerivio is an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in individuals aged 12 and older. Worn on the upper arm at the onset of a migraine attack, Nerivio alleviates migraine headache and associated symptoms by utilizing remote electrical neuromodulation to trigger an endogenous analgesic mechanism, known as conditioned pain modulation. Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options and can be used as a standalone treatment or in combination with existing treatments.
“This collaboration with Costco is a major step in helping us bring effective drug-free migraine relief to the millions of teens and adults in need,” said Alon Ironi, CEO of Theranica. “With its outstanding direct-to-customer policy, Costco is giving millions of under-insured and non-insured people affordable access to top quality prescription therapies, offering Nerivio as a first-line therapy. Moreover, the CMPP website helps members quickly receive a Nerivio prescription online, via a telemedicine consultation with a trained provider.”
The CMPP is a drug discount program that provides Costco members and their dependents the ability to obtain lower prices on prescription medications at participating pharmacies. All Costco members now gain access to Nerivio at an exclusive price, following a prescription from their health care provider or via a telemedicine consultation, and fulfilled by Miller’s Pharmacy online. Controlled by a smartphone app, Nerivio allows patients to treat their migraine attacks and monitor their results through a built-in migraine diary that is easily shared with healthcare providers for improved disease management.
“Tens of millions of Americans suffer from migraine and offering Nerivio to CMPP members supports our mission of providing safe, effective and clinically-validated relief to as many people as possible,” said Jen Stanton, Executive Director of Market Access at Theranica. “We are hopeful this will serve as a source of inspiration for other large retailers to bridge the gap between their customers and the effective migraine treatment they need.”
About Theranica
Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The company’s award-winning flagship wearable, Nerivio®, is the first FDA-cleared prescribed migraine REN wearable for acute and/or preventive treatment of migraine. Nerivio has been used in more than one million migraine treatments in the U.S., including by adolescents and veterans. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions.
Learn more by visiting our websites, theranica.com and nerivio.com and following us on LinkedIn, X(formerly Twitter), Instagram and Facebook.
Media Contact
Jennifer Sefakis
Grey Matter Marketing
jennifer@greymattermarketing.com
Theranica Contact
Ronen Jashek
